MerusMRUS
MRUS
About: Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Employees: 260
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
36% more call options, than puts
Call options by funds: $5.1M | Put options by funds: $3.75M
33% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 54
19% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 31
8% more funds holding in top 10
Funds holding in top 10: 12 [Q3] → 13 (+1) [Q4]
2% more funds holding
Funds holding: 188 [Q3] → 192 (+4) [Q4]
1.6% more ownership
Funds ownership: 101.19% [Q3] → 102.79% (+1.6%) [Q4]
14% less capital invested
Capital invested by funds: $3.45B [Q3] → $2.96B (-$494M) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$70
62%
upside
Avg. target
$86
99%
upside
High target
$109
152%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Needham Ami Fadia 12% 1-year accuracy 20 / 164 met price target | 92%upside $83 | Buy Reiterated | 9 Apr 2025 |
Guggenheim Michael Schmidt 27% 1-year accuracy 10 / 37 met price target | 152%upside $109 | Buy Reiterated | 28 Mar 2025 |
B of A Securities Tazeen Ahmad 25% 1-year accuracy 8 / 32 met price target | 62%upside $70 | Buy Maintained | 10 Mar 2025 |
HC Wainwright & Co. Andrew Fein 27% 1-year accuracy 95 / 352 met price target | 97%upside $85 | Buy Reiterated | 3 Mar 2025 |
Piper Sandler Joseph Catanzaro 48% 1-year accuracy 12 / 25 met price target | 94%upside $84 | Overweight Initiated | 13 Feb 2025 |
Financial journalist opinion
Positive
Seeking Alpha
2 weeks ago
Merus: Riding The Bispecific Wave In Oncology
Merus stands out in biotech with its innovative Biclonics and Multiclonics platforms, focusing on bispecific and multispecific antibodies, particularly petosemtamab. Strong financials with $724 million cash runway through 2028, allowing strategic R&D investments without immediate capital market pressures. Petosemtamab shows robust clinical data, receiving two FDA Breakthrough Therapy designations, indicating significant potential in treating HNSCC and other cancers.
Neutral
GlobeNewsWire
2 weeks ago
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025 at 8:45 a.m. ET.
Negative
Zacks Investment Research
1 month ago
Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates
Merus N.V. (MRUS) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $1.09 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25
Neutral
GlobeNewsWire
1 month ago
Merus to Present at Upcoming Investor Conferences
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Neutral
GlobeNewsWire
2 months ago
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Neutral
GlobeNewsWire
2 months ago
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Neutral
GlobeNewsWire
2 months ago
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the New England Journal of Medicine (NEJM) published results of the registrational phase 2 eNRGy trial for Bizengri® (zenocutuzumab), the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy.
Positive
Seeking Alpha
3 months ago
Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff
Bizengri's recent approval gives MRUS the first approved therapy for NRG1+ cancers, which, I think, will be a valuable niche. Petosemtamab's recent Phase 2 data for HNSCC suggests it could also have blockbuster potential as long as its Phase 3 trials are successful as well. I also like MRUS's recent partnership with BHVN as it gives it optionality with new ADC programs that could have oncology applications.
Neutral
GlobeNewsWire
3 months ago
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), today announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs), leveraging Merus' leading Biclonics® technology platform, and Biohaven's next-generation ADC conjugation and payload platform technologies.
Charts implemented using Lightweight Charts™